- Policy
- Next year’s reimb reevaluations to be discussed further
- by Lee, Tak-Sun Aug 29, 2025 06:07am
- The government has decided to continue discussions on the 2026 reimbursement adequacy reevaluation plan. While the reevaluation was initially expected to be approved this month through the Health Insurance Policy Deliberation Committee review, it is reported that disagreements remain unresolved regarding selection criteria, procedural i
- Policy
- Bill banning reverse payment agreements passes committee
- by Lee, Jeong-Hwan Aug 28, 2025 06:10am
- The amendment to the National Health Insurance Act, which regulates "reverse payment agreements" where original drug companies and generic drug companies collude by exchanging money to delay or not release generics, thereby avoiding a price reduction for the original drug, passed the National Assembly Health and Welfare Committee review on t
- Policy
- Reimb listing approved for the first generic of 'Angeliq'
- by Lee, Tak-Sun Aug 27, 2025 06:07am
- The first generic of Angeliq Tab (drospirenone·estradiol, Bayer), a hormone-based medicine for use in postmenopausal women, will be included in the reimbursement listing. Analysis suggests that the commercialization of domestically produced generic is significant, considering that there had been supply issues related to Angeliq, which is
- Policy
- ‘80,000 Wegovy prescriptions issued per month’
- by Lee, Jeong-Hwan Aug 27, 2025 06:06am
- The popular obesity drug Wegovy, which was launched in Korea in October last year, has already been prescribed about 400,000 times within eight months, raising concerns over potential misuse and abuse. On the 25th, Rep. Kim Sun-min of the Rebuilding Korea Party disclosed the ‘Annual and Monthly Status of Wegovy Prescriptions based on DUR
- Policy
- MFDS will intensively monitor Wegovy and other obesity drugs
- by Lee, Hye-Kyung Aug 26, 2025 06:05am
- The Ministry of Food and Drug Safety (MFDS) has designated ‘Wegovy’ and other GLP-1-class obesity injectables as targets for intensive monitoring and plans to continuously monitor side effects in collaboration with the Korea Institute of Drug Safety & Risk Management. Th MFDS designates the intensive monitoring status to drugs with high
- Policy
- SK chemicals' Afstyla will be removed from the reimb list
- by Lee, Tak-Sun Aug 25, 2025 06:08am
- SK chemicals' hemophilia A treatment, Afstyla, which was out-licensed by the company, will be removed from the reimbursement list due to a lack of record of supply performance. The product's delisting was previously deferred in 2023 through conditional negotiation, but with no sales to show since, the decision to remove it has become fina
- Policy
- NHIU ‘Eradicate rebates with INN-based prescriptions'
- by Lee, Tak-Sun Aug 25, 2025 06:06am
- The National Health Insurance Trade Union stressed the need to eradicate pharmaceutical rebates by improving the drug pricing system and distribution structure to those of advanced country standards. The union also advocated the introduction of generic substitution through international nonproprietary name prescriptions. On the 18th, it wa
- Policy
- IV formulation of Korea’s first IL-23 drug Tremfya approved
- by Lee, Hye-Kyung Aug 25, 2025 06:05am
- The intravenous injection formulation of Tremfya, the first interleukin-23 (IL-23) inhibitor in Korea, was recently granted approval, paving the way for the supply of all Tremfya injection formulations in Korea. On the 21st, the Ministry of Food and Drug Safety approved Janssen Korea's Tremfya Intravenous Injection (guselkumab, recombina
- Policy
- Blockbuster drugs, Atozet·Rosuzet, get price cuts
- by Lee, Tak-Sun Aug 22, 2025 06:07am
- It has been reported that prices for blockbuster drugs, including the hyperlipidemia combination therapies Atozet (Organon) and Rosuzet (Hanmi Pharmaceutical), are expected to be reduced due to increased usage. These hyperlipidemia combination therapies are frequently subject to annual volume-based drug price negotiations (PVA). Addit
- Policy
- ALS drug Qalsody is approved in Korea with a condition
- by Lee, Hye-Kyung Aug 22, 2025 06:07am
- The ALS treatment ‘Qalsody (tofersen)’ has been approved under the condition that the results of its therapeutic confirmatory clinical trial be submitted later. According to the advisory council’s review results regarding the safety and efficacy of Qalsody, which was released by the Ministry of Food and Drug Safety on the 20th, the cou
